Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertram Pitt

Showing results (361-370 of 688) with videos related to

Pageof 69
Sort By:
European Journal of Heart Failure|May 27, 2020
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCATJoão Pedro Ferreira, Xavier Rossello, Stuart J Pocock, et al.
The American Journal of Medicine|August 14, 2021
Post-COVID-19 Tachycardia Syndrome: A Distinct Phenotype of Post-Acute COVID-19 SyndromeMarcus Ståhlberg, Ulrika Reistam, Artur Fedorowski, et al.
European Heart Journal|July 19, 2013
The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trialTimothy J Collier, Stuart J Pocock, John J V McMurray, et al.
Circulation|October 9, 2012
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizationsJennifer K Rogers, John J V McMurray, Stuart J Pocock, et al.
Hypertension (Dallas, Tex. : 1979)|June 19, 2008
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failureBertram Pitt, Ali Ahmed, Thomas E Love, et al.
European Journal of Heart Failure|April 17, 2024
Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trialRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
Journal of Diabetes and Its Complications|February 12, 2026
Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITYRobert Weingold, Gerasimos Filippatos, Stefan D Anker, et al.
European Journal of Heart Failure|June 27, 2023
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trialLuca Monzo, Nicolas Girerd, Kevin Duarte, et al.
Circulation. Heart Failure|June 15, 2021
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF TrialJoão Pedro Ferreira, Zohra Lamiral, John J V McMurray, et al.
European Journal of Heart Failure|January 11, 2020
Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunctionPatrick Rossignol, Kevin Duarte, Nicolas Girerd, et al.
Pageof 69

Showing results (361-370 of 688) with videos related to

Sort By:
Pageof 69
European Journal of Heart Failure|May 27, 2020
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCATJoão Pedro Ferreira, Xavier Rossello, Stuart J Pocock, et al.
The American Journal of Medicine|August 14, 2021
Post-COVID-19 Tachycardia Syndrome: A Distinct Phenotype of Post-Acute COVID-19 SyndromeMarcus Ståhlberg, Ulrika Reistam, Artur Fedorowski, et al.
European Heart Journal|July 19, 2013
The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trialTimothy J Collier, Stuart J Pocock, John J V McMurray, et al.
Circulation|October 9, 2012
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizationsJennifer K Rogers, John J V McMurray, Stuart J Pocock, et al.
Hypertension (Dallas, Tex. : 1979)|June 19, 2008
History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failureBertram Pitt, Ali Ahmed, Thomas E Love, et al.
European Journal of Heart Failure|April 17, 2024
Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trialRahul Aggarwal, Deepak L Bhatt, Michael Szarek, et al.
Journal of Diabetes and Its Complications|February 12, 2026
Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITYRobert Weingold, Gerasimos Filippatos, Stefan D Anker, et al.
European Journal of Heart Failure|June 27, 2023
Time to clinical benefit of eplerenone among patients with heart failure and reduced ejection fraction: A subgroups analysis from the EMPHASIS-HF trialLuca Monzo, Nicolas Girerd, Kevin Duarte, et al.
Circulation. Heart Failure|June 15, 2021
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF TrialJoão Pedro Ferreira, Zohra Lamiral, John J V McMurray, et al.
European Journal of Heart Failure|January 11, 2020
Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunctionPatrick Rossignol, Kevin Duarte, Nicolas Girerd, et al.
Pageof 69